Trial Profile
A Phase II Trial of Perifosine (IND 58,156; NSC# 639966) in Biochemically Recurrent, Hormone Sensitive Prostate Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Perifosine (Primary)
- Indications Prostate cancer
- Focus Biomarker; Therapeutic Use
- 22 Feb 2015 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 07 Feb 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 19 Apr 2008 New trial record.